<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ911114-0045</DOCNO><DOCID>911114-0045.</DOCID><HL>   Business Brief -- A.L. Laboratories Inc.:   Tougher Regulation, Firings   Lead to 4th-Period Charge</HL><DATE>11/14/91</DATE><SO>WALL STREET JOURNAL (J), PAGE B4</SO><CO>   BMD</CO><MS>CONSUMER NON-CYCLICAL (NCY)</MS><IN>DRUG MANUFACTURERS (DRG)</IN><RE>EUROPE (EU)NEW JERSEY (NJ)NORTH AMERICA (NME)NORWAY (NOY)SCANDINAVIA (SCA)UNITED STATES (US)</RE><LP>   A.L. Laboratories Inc. said it will take a fourth-quartercharge of as much as $11 million because of tougher Food andDrug Administration rules governing pharmaceuticalproduction, and for current and projected work forcereduction costs.   A spokesman said 10 to 25 people have been terminated overthe past year. The company has about 700 employees at itsU.S. pharmaceutical operations, and about 1,800 world-wide.</LP><TEXT>   The generic drug and animal health-care products companybased in Fort Lee, N.J., is 50% owned by Norway'sApothekernes Laboratorium A.S.   For the third quarter, A.L. Labs posted flat net income of$3.7 million, or 21 cents a share on a fully-diluted basis.Revenue was $80 million up from $70 million in 1990.</TEXT></DOC>